MedTrace Logo

Pharmacokinetics Of Alprazolam Sublingual Tablet Versus Conventional Tablet

NCT01256151 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2021-01-28

No results posted yet for this study

Summary

To assess if the sublingual tablet will have similar pharmacokinetics as the conventional tablet of alprazolam.

Conditions

  • Anxiety Disorder

Interventions

DRUG

Alprazolam tablet

1 mg single dose of alprazolam conventional tablet

DRUG

Alprazolam sublingual

1 mg single dose of alprazolam sublingual tablet

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01256151 on ClinicalTrials.gov